Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 studyAnthony R. Mato, Michael Wang, Steven Le Gouill et al.|The Lancet|2021Cited by 456
Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic LeukemiaAnthony R. Mato, Wojciech Jurczak, Jennifer A. Woyach et al.|New England Journal of Medicine|2023Cited by 213
Assessment of the Efficacy of Therapies Following Venetoclax Discontinuation in CLL Reveals BTK Inhibition as an Effective StrategyAnthony R. Mato, Colleen Dorsey, Lindsey E. Roeker et al.|Clinical Cancer Research|2020Cited by 115
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2024William G. Wierda, Mary A. Dwyer, Jennifer R. Brown et al.|Journal of the National Comprehensive Cancer Network|2024Cited by 83
LOXO-305, A Next Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated CLL/SLL: Results from the Phase 1/2 BRUIN StudyAnthony R. Mato, Wojciech Jurczak, John M. Pagel et al.|Blood|2020Cited by 26